DREAMM-2: SINGLE-AGENT BELANTAMAB MAFODOTIN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA REFRACTORY TO PROTEASOME INHIBITORS, IMMUNOMODULATORY AGENTS, AND REFRACTORY AND/OR INTOLERANT TO ANTI-CD38 MABS
Author(s): ,
Sagar Lonial
Affiliations:
Emory University, Winship Cancer Institute,Atlanta, GA,United States
,
Hans C. Lee
Affiliations:
MD Anderson Cancer Center,Houston, TX,United States
,
Ashraf Badros
Affiliations:
University of Maryland at Baltimore,Baltimore, MD,United States
,
Suzanne Trudel
Affiliations:
Princess Margaret Cancer Centre,Toronto, ON,Canada
,
Ajay K. Nooka
Affiliations:
Emory University, Winship Cancer Institute,Atlanta, GA,United States
,
Ajai Chari
Affiliations:
Icahn School of Medicine at Mount Sinai,New York, NY,United States
,
Al-Ola Abdallah
Affiliations:
University of Kansas City Center,Fairway, KS,United States
,
Natalie Callander
Affiliations:
University of Wisconsin, Carbone Cancer Center,Madison, WI,United States
,
Douglas Sborov
Affiliations:
Huntsman Cancer Institute, University of Utah,Salt Lake City, UT,United States
,
Attaya Suvannasankha
Affiliations:
Indiana University Cancer Center,Indianapolis, IN,United States
,
Katja Weisel
Affiliations:
Medical Center of Hamburg-Eppendorf,Hamburg,Germany
,
Peter M. Voorhees
Affiliations:
Levine Cancer Institute, Atrium Health,Charlotte, NC,United States
,
Axel Hoos
Affiliations:
GlaxoSmithKline,Philadelphia, PA,United States
,
Eric Zhi
Affiliations:
GlaxoSmithKline,Philadelphia, PA,United States
,
January Baron
Affiliations:
GlaxoSmithKline,Philadelphia, PA,United States
,
Trisha Piontek
Affiliations:
GlaxoSmithKline,Philadelphia, PA,United States
,
Roxanne C. Jewell
Affiliations:
GlaxoSmithKline,Research Triangle Park, NC,United States
,
Joanna Opalinska
Affiliations:
GlaxoSmithKline,Philadelphia, PA,United States
,
Ira Gupta
Affiliations:
GlaxoSmithKline,Philadelphia, PA,United States
Adam D. Cohen
Affiliations:
Abramson Cancer Center, University of Pennsylvania,Philadelphia, PA,United States
EHA Library. Lonial S. 06/12/20; 294887; EP970
Prof. Sagar Lonial
Prof. Sagar Lonial
Contributions
Abstract

Abstract: EP970

Type: e-Poster

Presentation during EHA25: All e-Poster presentations will be made available on the on-demand Virtual Congress platform as of Friday, June 12 at 08:30 CEST and will be accessible until October 15, 2020.

Background
Investigational single-agent belantamab mafodotin (GSK2857916), a B-cell maturation antigen–targeting immunoconjugate, showed clinically meaningful activity and manageable safety in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM; DREAMM-2, NCT03525678, Lancet Oncol 2020). We report updated results (median follow-up 9 months).

Aims
-

Methods
DREAMM-2 is an ongoing single-agent belantamab mafodotin (2.5 or 3.4 mg/kg) study in patients with RRMM after ≥3 prior therapies and refractory to an immunomodulatory agent, a proteasome inhibitor, and refractory and/or intolerant to an anti-CD38 monoclonal antibody. Patients provided informed consent. Primary endpoint: overall response rate (ORR; ≥partial response per independent review committee). 

Results
ORR was 31% in the 2.5 mg/kg (19% with ≥very good partial responses [VGPR]) and 35% (24% with ≥VGPR) in the 3.4 mg/kg groups (Table). The median duration of response (DoR) was not reached (NR) in the 2.5 mg/kg and 6.2 months in the 3.4 mg/kg groups; 1-year overall survival (OS) estimate was 53%. Common Grade 3/4 AEs (>10% in either group) were keratopathy (2.5: 29%; 3.5: 24%), thrombocytopenia (2.5: 21%; 3.4: 32%), anemia (2.5: 20%; 3.4: 27%), pneumonia (2.5: 6%; 3.4: 13%), and neutropenia (2.5: 11%; 3.4: 16%). AEs were managed with dose delays (2.5: 54%; 3.4: 62%) and reductions (2.5: 34%; 3.4: 43%); discontinuations due to AEs were uncommon (2.5: 9%; 3.4: 12%).

Conclusion
Single-agent belantamab mafodotin was well tolerated, and clinically meaningful responses were sustained despite dose modifications with longer follow-up.


Funding: GlaxoSmithKline (205678). Drug linker technology licensed from Seattle Genetics; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): Clinical trial, Immunoconjugate, Multiple myeloma

© 2020 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2020 ASCO Annual Meeting. All rights reserved

Abstract: EP970

Type: e-Poster

Presentation during EHA25: All e-Poster presentations will be made available on the on-demand Virtual Congress platform as of Friday, June 12 at 08:30 CEST and will be accessible until October 15, 2020.

Background
Investigational single-agent belantamab mafodotin (GSK2857916), a B-cell maturation antigen–targeting immunoconjugate, showed clinically meaningful activity and manageable safety in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM; DREAMM-2, NCT03525678, Lancet Oncol 2020). We report updated results (median follow-up 9 months).

Aims
-

Methods
DREAMM-2 is an ongoing single-agent belantamab mafodotin (2.5 or 3.4 mg/kg) study in patients with RRMM after ≥3 prior therapies and refractory to an immunomodulatory agent, a proteasome inhibitor, and refractory and/or intolerant to an anti-CD38 monoclonal antibody. Patients provided informed consent. Primary endpoint: overall response rate (ORR; ≥partial response per independent review committee). 

Results
ORR was 31% in the 2.5 mg/kg (19% with ≥very good partial responses [VGPR]) and 35% (24% with ≥VGPR) in the 3.4 mg/kg groups (Table). The median duration of response (DoR) was not reached (NR) in the 2.5 mg/kg and 6.2 months in the 3.4 mg/kg groups; 1-year overall survival (OS) estimate was 53%. Common Grade 3/4 AEs (>10% in either group) were keratopathy (2.5: 29%; 3.5: 24%), thrombocytopenia (2.5: 21%; 3.4: 32%), anemia (2.5: 20%; 3.4: 27%), pneumonia (2.5: 6%; 3.4: 13%), and neutropenia (2.5: 11%; 3.4: 16%). AEs were managed with dose delays (2.5: 54%; 3.4: 62%) and reductions (2.5: 34%; 3.4: 43%); discontinuations due to AEs were uncommon (2.5: 9%; 3.4: 12%).

Conclusion
Single-agent belantamab mafodotin was well tolerated, and clinically meaningful responses were sustained despite dose modifications with longer follow-up.


Funding: GlaxoSmithKline (205678). Drug linker technology licensed from Seattle Genetics; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): Clinical trial, Immunoconjugate, Multiple myeloma

© 2020 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2020 ASCO Annual Meeting. All rights reserved

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies